To Fight EID, Think Global, Act Local Our response to Emerging Diseases is considered on a global basis, but implementation is regional – The risk and impact of an EID is unique to a particular region e.g. AHS in Europe – The need and type of intervention is unique to the region e.g. FMD – The pathogen itself may have unique properties e.g. PRRS Achieving a rapid response requires planning and communication between industry and local and regional governments and regulatory authorities – Time lines to mass production of a vaccine can be shortened if production and testing systems are already prepared 10/10/20151

Pfizer Animal Health  A Pfizer business  A leading global animal health company  Working to assure a safe, sustainable global food supply from healthy beef and dairy cattle, swine, poultry and fish  Helping dogs, cats and horses live healthier longer lives

Pfizer Animal Health (PAH) World leader in discovery, development, and manufacture of veterinary vaccines & medicines 700+ veterinary R&D scientists and specialists worldwide Diverse portfolio of leading veterinary products & services for livestock & companion animals Operating in 60+ countries

PAH Leader in Global R&D Investment R&D Spend in $Millions PAH R&D $300 million + Source: Vetnosis Income Statement Report, released September 2009 Mon- santoAlpharmaVeto- quinolCEVAJ&JMerialI/SPPfizer (2010B) ElancoBayerNovartisBIVVirbac

PAH Global R&D Network Lincoln Nebraska Charles City Iowa Thane India Melbourne Australia Olot Spain Louvain-la-Neuve Belgium Kalamazoo Michigan Sandwich UK Zaventem Belgium

Complementary Businesses to Provide Total Solutions Nutrition/ Vitamins/ Probiotics Diagnostics Animal Healthcare Providers Producers Pet owners Vets/Clinics Genetics Business Services Generics Tech Services Innovative products Aquaculture Food Safety PAH core business PAH recently entered PAH under evaluation

Rapid Development of H1N1 Vaccine for Swine Pfizer Animal Health developed a vaccine with USDA support to protect swine from the U.S. outbreak of the H1N1 virus  First industry partner to receive USDA approval for H1N1 vaccine  Developed vaccine in a record 4-month period  Scientific Development  Manufacturing Scale-up  Commercial Justification  Regulatory Approvals  Partnered with a ONE TEAM Approach across PAH and USDA  Prudent risk-taking & innovations  Strain selection, parallel efforts in scale-up and clinical studies  Manufacture of extensive supplies before market needs were fully defined,  Bioreactor, lyophilization cycle

PAH investment in EID vaccines EIDs are an increasing global health issue There is an increasing risk for new EIDs in the future: – Increasing global travel – Increasing world food trade – Increasing demand for protein 10/10/20158

PAH investment in EID vaccines Louvain-La-Neuve facility has been identified as Pfizer’s European center of excellence for the development and production of vaccine solutions against emerging infectious diseases Offers advanced capabilities in development and production of vaccines both in expertise and equipment Is physically close to local and regional governments and regulatory authorities to facilitate frequent interaction and communication 10/10/20159

Major Innovation in Pork Production  Favorable to animal welfare and the environment  Allows producers to raise pigs using less feed while enhancing meat quality  Avoids infections and complications that can be caused by physical castration Improvac allows stakeholders across the pork production chain to reap the benefits of natural boar growth

Pfizer Animal Health in China Focus on PAH Goals – Working to assure a safe, sustainable global food supply from health beef and dairy cattle, swine and fish – Help dogs, cats and horses live healthier and longer Introduce high quality animal products to local market – Improvac – Improve meat quality – Low dose and long acting antibiotic s - Draxxin and Excede – Low residue pharmaceutics products - Lincomix ® Feed Medication The only FDA-approved antimicrobial treatment of ileitis and mycoplasmal pneumonia with a zero-day withdrawal Develop products fitting local need – Identified need for local market – Initiate R&D work for local products